Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells

Cell Cycle

Volumn 11, Issue 17, 2012, Pages 3219-3226

  Romanski, Annette ^a   Schwarz, Kerstin ^a   Keller, Maren ^a   Wietbrauk, Sarah ^a   Vogel, Anja ^a   Roos, Jessica ^a   Oancea, Claudia ^a   Brill, Boris ^b   Krämer, Oliver H ^c   Serve, Hubert ^a   Ruthardt, Martin ^a   Bug, Gesine ^a  

^a GOETHE UNIVERSITY   (Germany)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Acute myeloid leukemia; BMI1; Dacinostat; Deacetylase inhibitor; Leukemic stem cells; Self renewal; Short term repopulation; Vorinostat

Indexed keywords

BMI1 PROTEIN; DACINOSTAT; MYC PROTEIN; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; EXON; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; NONHUMAN;

MURINAE;

EID: 84866288213     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21565     Document Type: Article

References (42)

1. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367:645-8; PMID:7509044; http://dx.doi.org/10.1038/ 367645a0
2. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730-7; PMID:9212098; http://dx.doi.org/10.1038/nm0797-730
3. Romanski A, Bacic B, Bug G, Pfeifer H, Gul H, Remiszewski S, et al. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica 2004; 89:419-26; PMID:15075075
4. Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005; 104:2717-25; PMID:16294345; http://dx.doi.org/10.1002/cncr.21589
5. Fiskus W, Buckley K, Rao R, Mandawat A, Yang Y, Joshi R, et al. Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol Ther 2009; 8:939-50; PMID:19279403; http://dx.doi.org/10. 4161/cbt.8.10.8213
6. Buchwald M, Krämer OH, Heinzel T. HDACi - targets beyond chromatin. Cancer Lett 2009; 280:160-7; PMID:19342155; http://dx.doi.org/10.1016/j.can-let. 2009.02.028
7. Zheng X, Beissert T, Kukoc-Zivojnov N, Puccetti E, Altschmied J, Strolz C, et al. Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood 2004; 103:3535-43; PMID:14739224; http://dx.doi.org/10. 1182/blood-2003-09-3335
8. Yan M, Burel SA, Peterson LF, Kanbe E, Iwasaki H, Boyapati A, et al. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci USA 2004; 101:17186-91; PMID:15569932; http://dx.doi.org/10.1073/pnas.0406702101
9. Müller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004; 24:2890-904; PMID:15024077; http://dx.doi.org/10.1128/MCB.24.7.2890-2904.2004
10. Rice KL, Hormaeche I, Doulatov S, Flatow JM, Grimwade D, Mills KI, et al. Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood 2009; 114:5499-511; PMID:19855079; http://dx.doi.org/10.1182/blood-2009-03-206524
11. Luo H, Li Q, O'Neal J, Kreisel F, Le Beau MM, Tomasson MH. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood 2005; 106:2452-61; PMID:15972450; http://dx.doi.org/10.1182/blood-2005-02-0734
12. Xiang Z, Luo H, Payton JE, Cain J, Ley TJ, Opferman JT, et al. Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. J Clin Invest 2010; 120:2109-18; PMID:20484815; http://dx.doi.org/10.1172/JCI39964
13. Guo WJ, Datta S, Band V, Dimri GP. Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins. Mol Biol Cell 2007; 18:536-46; PMID:17151361; http://dx.doi.org/10.1091/mbc.E06-05-0447
14. Boukarabila H, Saurin AJ, Batsché E, Mossadegh N, van Lohuizen M, Otte AP, et al. The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev 2009; 23:1195-206; PMID:19451220; http://dx.doi.org/10.1101/gad.512009
15. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006; 6:846-56; PMID:17060944; http://dx.doi.org/10.1038/nrc1991
16. Ottmann O, Spencer A, Prince H, Bhalla K, Fischer T, Liu A, et al. Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies. Blood 2008; 112:a958.
17. Burbury KL, Bishton MJ, Johnstone RW, Dickinson MJ, Szer J, Prince HM. MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi). Ann Hematol 2011; 90:847-9; PMID:20949272; http://dx.doi.org/10.1007/s00277-010-1099-6
18. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111:1060-6; PMID:17962510; http://dx.doi.org/10.1182/blood-2007-06-098061
19. Schwarz K, Romanski A, Puccetti E, Wietbrauk S, Vogel A, Keller M, et al. The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells. Leuk Res 2011; 35:119-25; PMID:20674020; http://dx.doi.org/10. 1016/j.leukres.2010.06.024
20. Coulombel L. Identification of hematopoietic stem/progenitor cells: strength and drawbacks of functional assays. Oncogene 2004; 23:7210-22; PMID:15378081; http://dx.doi.org/10.1038/sj.onc.1207941
21. Zheng X, Seshire A, Puccetti E, Gul H, Beissert T, Hoelzer D, et al. The acute promyelocytic leukemia-associated fusion protein PML/RAR blocks t-RA-induced differentiation in a subset of cells with stem cell potential. Blood 2004; 11:333a.
22. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003; 423:255-60; PMID:12714970; http://dx.doi.org/10.1038/nature01572
23. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000; 97:10014-9; PMID:10954755; http://dx.doi.org/10.1073/pnas.180316197
24. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115:453-74; PMID:19880497; http://dx.doi.org/10.1182/blood-2009-07-235358
25. Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies". Blood 2000; 96:1297-308; PMID:10942371
26. Estey E. High cytogenetic or molecular genetic risk acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2010; 2010:474-80; PMID:21239839.
27. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al.; German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1909-18; PMID:18450602; http://dx.doi.org/10. 1056/NEJMoa074306
28. Huntly BJ, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004; 6:587-96; PMID:15607963; http://dx.doi.org/10.1016/j.ccr.2004.10.015
29. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 1998; 18:126-35; PMID:9462740; http://dx.doi.org/10.1038/ng0298-126
30. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 1997; 16:4226-37; PMID:9250666; http://dx.doi.org/10.1093/emboj/16.14. 4226
31. Puccetti E, Zheng X, Brambilla D, Seshire A, Beissert T, Boehrer S, et al. The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARalpha. Cancer Res 2005; 65:6080-8; PMID:16024608; http://dx.doi.org/10. 1158/0008-5472.CAN-04-3631
32. van Gosliga D, Schepers H, Rizo A, van der Kolk D, Vellenga E, Schuringa JJ. Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Exp Hematol 2007; 35:1538-49; PMID:17889721; http://dx.doi.org/10.1016/j.exphem.2007.07.001
33. Rizo A, Olthof S, Han L, Vellenga E, de Haan G, Schuringa JJ. Repression of BMI1 in normal and leukemic human CD34(+) cells impairs self-renewal and induces apoptosis. Blood 2009; 114:1498-505. PMID:19556423; http://dx.doi.org/ 10.1182/blood-2009-03-209734
34. Bommi PV, Dimri M, Sahasrabuddhe AA, Khandekar JD, Dimri GP. The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors. Cell Cycle 2010; 9:2663-73; PMID:20543557; http://dx.doi.org/10.4161/cc.9.13.12147
35. Wang R, Brunner T, Zhang L, Shi Y. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression. Oncogene 1998; 17:1503-8; PMID:9794227; http://dx.doi.org/10.1038/sj.onc.1202059
36. Skov S, Rieneck K, Bovin LF, Skak K, Tomra S, Michelsen BK, et al. Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression. Blood 2003; 101:1430-8; PMID:12393479; http://dx.doi.org/10.1182/blood-2002-07-2073
37. Xu Y, Voelter-Mahlknecht S, Mahlknecht U. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. Int J Mol Med 2005; 15:169-72; PMID:15583844
38. Wang LG, Liu XM, Fang Y, Dai W, Chiao FB, Puccio GM, et al. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 2008; 33:375-80; PMID:18636159
39. Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, et al. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 2010; 150:72-82; PMID:20456355
40. Rossmanith T, Schröder B, Bug G, Müller P, Klenner T, Knaus R, et al. Interleukin 3 improves the ex vivo expansion of primitive human cord blood progenitor cells and maintains the engraftment potential of scid repopulating cells. Stem Cells 2001; 19:313-20; PMID:11463951; http://dx.doi.org/10.1634/stem-cells.19-4-313
41. Puccetti E, Obradovic D, Beissert T, Bianchini A, Washburn B, Chiaradonna F, et al. AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor. Cancer Res 2002; 62:7050-8; PMID:12460926
42. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Method. Methods 2001; 25:402-8; PMID:11846609; http://dx.doi.org/10.1006/meth.2001.1262